Glioblastoma multiforme (GBM) is one of the most common and aggressive primary brain tumors, composing 12%–20% of all intracranial tumors in adults. Average life expectancy is merely 12–14 months following initial diagnosis. Patients with this neoplasm have one of the worst 5-year survival rates among all cancers despite aggressive multimodal treatment consisting of maximal tumor resection, radiation therapy, and adjuvant chemotherapy. With recent advancements in management strategies, there has been improvement in the overall trend in patient outcomes; however, recurrence remains nearly inevitable. While most tumors recur locally, metastases to distal locations have become more common. Specifically, the last decade has seen an increased incidence of spinal metastases, representing an emerging complication in patients with intracranial GBM. However, the literature regarding prevention strategies and the presentation of spinal metastases has remained scarce. As local control of primary lesions continues to improve, more cases of spinal metastases are likely to be seen. In this review the authors present a new case of metastatic GBM to the L-5 nerve root, and they summarize previous cases of intracranial GBM with leptomeningeal spinal metastatic disease. They also characterize key features of this disease presentation and discuss areas of future investigation necessary for enhanced prevention and treatment of this complication.
Abbreviation used in this paper:GBM = glioblastoma multiforme.
Address correspondence to: Zachary A. Smith, M.D., Department of Neurological Surgery, Suite 2210, Northwestern University, 676 North St. Clair Street, Chicago, Illinois 60661. email: email@example.com.
Please include this information when citing this paper: published online September 7, 2012; DOI: 10.3171/2012.7.SPINE12212.
BrandesAATosoniAFranceschiESottiGFrezzaGAmistàP: Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol27:1275–12792009
CurranWJJrScottCBHortonJNelsonJSWeinsteinASFischbachAJ: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst85:704–7101993
DavisFGFreelsSGrutschJBarlasSBremS: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg88:1–101998
ErpolatOPAkmansuMGokselFBoraHYamanEBüyükberberS: Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori95:191–1972009
HataNKatsutaTInoueTArikawaKYanoTTakeshitaM: [Extracranial metastasis of glioblastoma to the lung and heart with a histological resemblance to small cell carcinoma of the lung: an autopsy case.]. No Shinkei Geka29:433–4382001. (Jpn)
KristiansenKHagenSKollevoldTTorvikAHolmeINesbakkenR: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer47:649–6521981
LeeSWFraassBAMarshLHHerbortKGebarskiSSMartelMK: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys43:79–881999
MedhkourAChanM: Extremely rare glioblastoma multiforme of the conus medullaris with holocord and brain stem metastases, leading to cranial nerve deficit and respiratory failure: a case report and review of the literature. Surg Neurol63:576–5832005
PoharSTaylorWChandanVSShahHSagermanRH: Primary presentation of glioblastoma multiforme with leptomeningeal metastasis in the absence of previous craniotomy: a case report. Am J Clin Oncol27:640–6412004
StummerWPichlmeierUMeinelTWiestlerODZanellaFReulenHJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol7:392–4012006
StuppRHegiMEMasonWPvan den BentMJTaphoornMJJanzerRC: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol10:459–4662009
TsengHMKuoLTLienHCLiuKLLiuMTHuangCY: Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. Anticancer Drugs21:963–9672010